AWM
VRTX icon

Axxcess Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Axxcess Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$533K Buy
+1,074
New +$476K 0.01% 699
2026
Q1 		– Sell
-565
Closed -$256K – 989
2025
Q4 		$256K Buy
+565
New +$244K ﹤0.01% 900
2025
Q1 		– Sell
-1,052
Closed -$424K – 942
2024
Q4 		$424K Sell
1,052
-1,798
-63% -$833K 0.01% 584
2024
Q3 		$1.33M Buy
2,850
+405
+17% +$195K 0.03% 335
2024
Q2 		$1.15M Buy
2,445
+217
+10% +$94.2K 0.03% 345
2024
Q1 		$931K Buy
2,228
+560
+34% +$237K 0.03% 387
2023
Q4 		$679K Sell
1,668
-329
-16% -$122K 0.02% 443
2023
Q3 		$694K Buy
1,997
+685
+52% +$240K 0.02% 386
2023
Q2 		$462K Buy
1,312
+60
+5% +$20.2K 0.03% 369
2023
Q1 		$394K Sell
1,252
-691
-36% -$207K 0.03% 422
2022
Q4 		$561K Sell
1,943
-903
-32% -$275K 0.05% 339
2022
Q3 		$824K Sell
2,846
-262
-8% -$75.4K 0.08% 219
2022
Q2 		$876K Buy
3,108
+22
+0.7% +$5.89K 0.08% 209
2022
Q1 		$805K Buy
3,086
+378
+14% +$89.7K 0.06% 261
2021
Q4 		$595K Buy
+2,708
New +$527K 0.04% 318

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Axxcess Wealth Management's VRTX Position: Q2 2026 in Review

Axxcess Wealth Management opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 1,074 shares worth $533K. The stake represents 0.01% of the portfolio and ranks #699 among its holdings. This is a return to the name: Axxcess Wealth Management previously reported a position in VRTX as recently as Q4 2025.

Axxcess Wealth Management first reported a position in VRTX in Q4 2021 and has held it in 15 quarters since. The position peaked at $1.33M in Q3 2024. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Axxcess Wealth Management held 1,074 shares of Vertex Pharmaceuticals worth $533K as of Q2 2026.
  • Vertex Pharmaceuticals was a new Axxcess Wealth Management position in Q2 2026.
  • Vertex Pharmaceuticals made up 0.01% of Axxcess Wealth Management's portfolio in Q2 2026, its #699 holding.
  • Axxcess Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 15 quarters since.
  • Axxcess Wealth Management's Vertex Pharmaceuticals position peaked at $1.33M in Q3 2024.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Axxcess Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.